Gilead Sciences, Inc.
GILD · Healthcare
$149.92
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ
Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's stock has fallen 19.5% in six months due to several clinical and pipeline setbacks, including failed studies for Wainua and Ultomiris, and FDA delays for camizestrant. However, the company maintains solid fundamentals with 16 blockbuster drugs, 15% oncology sales growth, and targets $80 billion in revenues by 2030 with 20 new medicines planned. Despite headwinds from patent expirations and China market uncertainties, analysts recommend staying invested given growth prospects.
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Eli Lilly announced its 10th acquisition of 2026, agreeing to acquire Merida Biosciences for up to $2.875 billion to strengthen its immunology pipeline. The company is strategically diversifying its portfolio across oncology, immunology, neuroscience, and vaccines to reduce reliance on GLP-1 medicines (Mounjaro and Zepbound), which currently account for 65% of revenues. Other major pharma companies including Merck, Gilead Sciences, and AbbVie are also pursuing significant M&A deals to expand pipelines and enter new therapeutic areas.
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead Sciences received FDA approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults unable to take current treatments. The company raised its 2026 HIV sales growth outlook to 9-10%, driven by flagship drugs Biktarvy, Descovy, and the rapidly growing Yeztugo injectable PrEP. Bixlenvo and Gilead's expanding lenacapavir pipeline offer additional growth opportunities in HIV treatment and prevention.
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
The article compares brokerage analyst recommendations (ABR) with Zacks Rank, arguing that while Gilead Sciences has a strong Buy-equivalent ABR of 1.52 from 31 firms, brokerage recommendations suffer from positive bias due to institutional conflicts of interest. The Zacks Rank, based on earnings estimate revisions rather than analyst opinions, is presented as a more reliable predictor of near-term stock performance. Gilead received a Zacks Rank #1 (Strong Buy) rating due to a 40.4% increase in consensus earnings estimates over the past month.